1. Home
  2. SON vs TGTX Comparison

SON vs TGTX Comparison

Compare SON & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sonoco Products Company

SON

Sonoco Products Company

HOLD

Current Price

$53.19

Market Cap

4.7B

ML Signal

HOLD

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$27.42

Market Cap

4.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SON
TGTX
Founded
1899
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Containers/Packaging
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.7B
4.9B
IPO Year
2014
2008

Fundamental Metrics

Financial Performance
Metric
SON
TGTX
Price
$53.19
$27.42
Analyst Decision
Buy
Strong Buy
Analyst Count
8
5
Target Price
$63.00
$49.80
AVG Volume (30 Days)
1.0M
1.4M
Earning Date
05-20-2026
05-29-2026
Dividend Yield
4.02%
N/A
EPS Growth
510.30
1746.67
EPS
10.07
2.77
Revenue
$7,518,753,000.00
$2,785,000.00
Revenue This Year
$0.03
$48.75
Revenue Next Year
$2.01
$25.01
P/E Ratio
$5.24
$9.72
Revenue Growth
41.72
N/A
52 Week Low
$38.65
$25.37
52 Week High
$58.44
$46.48

Technical Indicators

Market Signals
Indicator
SON
TGTX
Relative Strength Index (RSI) 49.58 37.66
Support Level $43.24 $25.37
Resistance Level $58.44 $32.77
Average True Range (ATR) 1.40 1.15
MACD -0.62 -0.23
Stochastic Oscillator 23.57 13.31

Price Performance

Historical Comparison
SON
TGTX

About SON Sonoco Products Company

Over its 100-year-plus history, Sonoco Products has steadily assembled a diverse portfolio of industrial and consumer packaging product offerings such as flexible and rigid plastics, reels and spools, pallets, and composite cans. The company serves a variety of consumer and industrial end markets throughout North America. Sonoco has raised its dividend each year for more than 40 years.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

Share on Social Networks: